When is endocervical curettage (ECC) recommended as part of the evaluation of postmenopausal vaginal bleeding? —Mary McCrossan, MD, Wilmington, Del. ECC is warranted in a woman with postmenopausal ...
Emily Fukuchi, MD; Barbara Fetterman, SCT (ASCP); Nancy Poitras, ACS, PMP; Walter Kinney, MD; Thomas Lorey, MD; Ramey D. Littell, MD To evaluate whether the presence of CIN 1 on ECC contributes to ...
When a woman has an abnormal pap smear she usually undergoes colposcopy. Typically a metal instrument is used to obtain a small sampling of cells inside the cervix -- an oftentimes painful procedure ...
ATLANTA, May 03, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally ...
Phase II trial of paclitaxel plus doxorubicin plus carboplatin in patients with intermediate risk, high risk, or recurrent endometrial carcinoma No significant financial relationships to disclose.
Femasys Inc., a medical device developer of women's healthcare solutions, announced today the U.S. launch of the 510(k) cleared FemCerv™, an innovative endocervical curettage device. FemCerv is ...
ATLANTA, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally ...
The adjusted incidence of cervical carcinoma among Israeli Jewish women is ∼5 out of 100 000. This retrospective study sought to determine the clinical implications of finding atypical glandular cells ...
Ms Y, a 30-year-old Caucasian, is self-referred for an annual examination. She reports a history of abnormal Pap test results and wants to establish care with a provider in the city to which she has ...
Tolerability of long-term use of trabectedin (Tr) in combination with pegylated liposomal doxorubicin (PLD) in patients (pts) with relapsed ovarian cancer (ROC). Background: Our objective is to ...
There are limited data and guidance from the UK on borderline nuclear change in endocervical cells (BNCs). The objective of this study is to determine the clinical outcome of women with BNCs, to ...
Objective. This study aimed to characterize the 24-month risk of cervical intraepithelial neoplasia grade 2 or worse (CIN 2+) and grade 3 or worse (CIN 3+) in women with low-risk cytological finding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results